AM-Pharma BV of the Netherlands has raised €12.2 million for the further clinical development of its recombinant human alkaline phosphatase product for acute kidney injury and ulcerative colitis – its second major fundraising in three years
Alizé Pharma SAS has raised €5 million to finance further development of an analog of a metabolic hormone that has the potential to treat type-2 diabetes and a rare children’s disease called the Prader-Willi syndrome.
Genmab A/S is expanding its involvement in antibody-drug conjugates (ADCs) with a new agreement to in-license technology from Seattle Genetics Inc. Under the latest deal, the Danish company will develop an ADC for potential use against solid tumours.
Biocartis NV, a Belgian developer of molecular diagnostics, has raised €64.5 million in equity finance to support the commercialisation of its Idylla diagnostic system.
In keeping with the trend among European biotechs to finance themselves in the US, Ablynx NV of Belgium has started an open-ended programme of selling its shares on the US over-the-counter market through the creation of American Depository Receipts (ADRs).
In the latest of a series of single asset deals among biopharma firms, AbbVie Inc has agreed to pay up to $805 million for rights to a mid-stage cancer drug being developed by Infinity Pharmaceuticals Inc with potential applications in a broad range of blood cancers.
Affimed Therapeutics AG, which is in the queue to make an initial public offering of its shares in the US, has in the meantime obtained $29.7 million from its venture investors and Perceptive Advisors LLC of New York City.
Medtronic Inc has paid €150 million in cash to acquire Sapiens Steering Brain Stimulation BV, a Dutch company developing deep brain stimulation technologies for the treatment of the movement symptoms of Parkinson’s disease.
An indirect affiliate of Johnson & Johnson Inc, Cilag GmbH International of Zug, Switzerland, has acquired Covagen AG from Covagen’s venture capital and other private investors for an undisclosed amount.
The Roche Group is to acquire InterMune Inc of the US for $8.3 billion in cash in order to gain access to that company’s respiratory portfolio that includes a marketed product for idiopathic pulmonary fibrosis. The deal has been approved by the boards of both companies.